Severe fever with thrombocytopenia syndrome (SFTS) is a newly emerging infectious disease, caused by a novel species of Phlebovirus of Bunyaviridae family, in China, South Korea, and Japan. SFTS is primarily known as a tick-borne disease, and human-to-human transmission is also possible in contact with infectious blood. Common clinical manifestations include fever, thrombocytopenia, and leukopenia as initial symptoms, and multiple organ dysfunction and failure manifest with disease progression. Whereas disease mortality is reported to be 12% to 30% in China, a recent report of cumulative SFTS cases indicated 47% in Korea. Risk factors associated with SFTS were age, presence of neurologic disturbance, serum enzyme levels, and elevated concentrations of certain cytokines. Diagnosis of SFTS is based on viral isolation, viral identification by polymerase chain reaction, and serologic identification of specific immunoglobulin G. Therapeutic guideline has not been formulated, but conservative management is the mainstream of treatment to prevent disease progression and fatal complications.
INTRODUCTION
Since its first identification in China in 2006, the incidence of newly emerging infectious disease, Severe Fever with Thrombocytopenia Syndrome (SFTS), has been consistently increasing in northeastern Asian countries including China, South Korea, and Japan. [1] [2] [3] Vector of SFTS is primarily reported to be Haemaphysalis longicornis, which is also known for other tick-borne diseases such as Lyme disease, rickettsia, and spotted fever. Despite a lack of thorough understanding of disease progression, clinical manifestations initially include fever, gastrointestinal symptoms, thrombocytopenia, leukopenia, and bleeding tendency. In critically ill patients, the conditions rapidly progress to multiple organ failure and death, whose mortality reported 12% to 30%. [4] The current review is based on the collection of data reported in previous studies regarding SFTS and its virus. This paper systematically reviews epidemiology, transmission, clinical symptoms, diagnosis, and treatment. Information described herein is believed to improve understanding of the newly emerging infectious disease and virus and to help to not only prevent but also control disease progression in endemic areas.
EPIDEMIOLOGY
SFTS virus is a RNA virus, a novel Phlebovirus species in Bunyaviridae family, first retrospectively isolated in China from a 42-year-old male occurred in 2006. [5] Until 2012, the accumulated death from SFTS was described to be 129 from 2,047 infected cases in China. [6] The first reported Japanese SFTS case occurred in Yamaguichi prefecture in 2012, and a retrospective study further identified 6 more SFTS cases in western provinces of Japan. [3] The first SFTS occurrence outside Asia was identified in the United Arab Emirate from a temporary North Korean resident in 2011, which suggests a potential SFTS infection in North Korea. [7] In South Korea, the first clinically suspected patient was detected on Jeju Island on May 2013, and the first viral isolation was reported by Seoul National University Hospital from a retrospective study. [8, 9] Until November 2013, a report from Korean Center for Disease Control indicated that cumulative confirmed cases of SFTS were 36 out of 404 suspicious cases, and fatal cases were 17 in South Korea. [10] Among the reported cases, more than 90% of patients were older than 35 years of age with a median age of 58 years, and farmers were the most affected population. [6] SFTS infection also showed seasonal distribution with biphasic peaks of incidence in May to June and August to September. Such seasonal occurrence especially in early summer and late fall seems to be attributed to increased outdoor activity. [2] 
ROUTE OF TRANSMISSION
SFTS is primarily known to be a tick-borne disease, vector of which is predominantly H. longicornis with greater prevalence and in some cases Rhipicephalu microplus with lesser prevalence in epidemic and non-epidemic area, respectively. [6, 11] A history of tick exposure was found in 52% of SFTS patients, and nucleic acid sequences of SFTS virus isolated from the ticks that were collected from mammals and environment in endemic areas showed 95% to 100% homology with that isolated from the patients. [2] Analysis of seroprevalence in mammals such as goats, cattle, and dogs infested with ticks indicated antibody positivity up to 57%. [12] Tang et al. [13] reported that human-to-human transmission in cases of unprotected contact with SFTS patients or contact with infectious blood and bodily fluid. Viral RNA was detected in blood, throat, urine, and fecal specimen. [4] Most secondary SFTS infections occurred in a family cluster, and non-familial secondary infection was reported in patients in proximity to the infected patient and healthcare workers. [14] Interpersonal transmission of SFTS virus is more probable from critically ill patients whose blood concentration of SFTS virus is increased.
Reported vulnerable population was a doctor performing tracheal intubation, a consultant doctor exposed to infectious blood from intravenous lines, and a local mortuary beautician managing the corpse. [15] Secondary infection should be closely monitored at least for the incubation period (> 13 days) because possibility of transmission is increased more than 3 times in contact with infectious blood and in exposure of blood to mucosal membrane; therefore, personal protective measures are critical in dealing with infected patients and dead patients. [13] 
CLINICAL MANIFESTATION AND LABORATORY FINDINGS
Upon time of viral transmission, incubation period of SFTS virus is reported to be 6 to 14 days, and eschar-like cutaneous lesion, usually round, crust bearing, and ulcerative, is commonly associated with tick bite. [16] Even though history of tick bite is common in SFTS infection, tick bite is not evident in some patients. Because most SFTS patients are older population, it is common that they often do not recall history of tick bite. Ticks are attracted to mammals by exhaled carbon dioxide, and because ticks spit back chemicals to prevent itching symptoms in patients after sucking host's blood, patients may not potentially sense the bites. Therefore, although history of tick bite is helpful in diagnosis of SFTS, history of outside activity should be considered more carefully.
Even though some are self-limited without any symptoms, most infected patients commonly complain of fever, myalgia, arthralgia and gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea. Mortality rate is reported from 6% to 30% in previous Chinese reports, but the most up-to-dated report from Korean Therefore, it is best to find nearby medical facilities when tick bite is suspected. When SFTS infection is confirmed, the patient is recommended for isolation, and healthcare workers are advised to wear personal protective equipment to prevent human-to-human transmission. 
CONCLUSION

